BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-3579
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2015English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

Clinical Cancer Research
Cancer ResearchOncology
2016English

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib

Clinical Cancer Research
Cancer ResearchOncology
2014English

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Comment on “ERK and P38MAPK Combine to Improve Survival in Patients With BRAF Mutant Colorectal Cancer”

British Journal of Cancer
Cancer ResearchOncology
2018English

BRAF Mutant Colorectal Cancer: ErbB2 Expression Levels as Predictive Factor for the Response to Combined BRAF/ErbB Inhibitors

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy